Seres Therapeutics, Inc. and Nestlé Health Science announced the U.S. Food and Drug Administration approval of VOWSTTM, formerly called SER-109, an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection in adults following antibacterial treatment for recurrent CDI.
